BPC-157 vs TB-500: How the Research Compares

What are BPC-157 and TB-500?

BPC-157 is a 15-amino-acid peptide, GEPPPGKPADDAGLV, with a molecular weight of about 1419 Da. It is a partial sequence of a larger protein, body protection compound, isolated from human gastric juice, and was reported to be stable in that environment^1,2. Under the code PL 14736 it entered early clinical trials for inflammatory bowel disease¹.

TB-500 is the name under which anti-doping laboratories found the N-terminally acetylated 17-23 fragment of human thymosin beta-4, Ac-LKKTETQ, a seven-residue peptide of about 889 Da³. Thymosin beta-4 itself is a 43-amino-acid protein and the major actin-sequestering molecule in eukaryotic cells; LKKTETQ sits in its central actin-binding domain⁴.

Because the two names are often mentioned together, and sold together in blends such as the Wolverine Blend, they are sometimes assumed to be related. They are not: they share no sequence, come from different parent proteins and have no established common receptor.

BPC-157 vs TB-500 at a glance

The table summarizes the comparison. The evidence behind each row is cited in the sections that follow.

How they are thought to work

BPC-157's mechanism has not been pinned down to a single pathway or receptor⁵. In rat tendon fibroblasts it increased migration, spreading and survival under oxidative stress, with concentration-dependent phosphorylation of FAK and paxillin, but did not directly increase proliferation². In human endothelial cells and ischemic rat muscle it raised VEGFR2 expression and activated VEGFR2-Akt-eNOS signaling⁶, and the originating group has repeatedly linked its effects to the nitric oxide system¹.

TB-500's rationale is structural. Thymosin beta-4's actin-binding domain has been linked to angiogenesis, wound repair and cell migration⁴, and an NIH group showed that the seven-residue motif was essential for the protein's angiogenic activity: on its own it matched full thymosin beta-4 in endothelial migration and aortic-ring sprouting assays, while peptides lacking part of the motif were inactive⁷. A 2024 metabolism study complicates the picture. In rats TB-500 was broken down into shorter fragments, chiefly Ac-LK in the first hours, and in fibroblast assays the metabolite Ac-LKKTE, not the parent peptide, showed significant wound-closure activity⁸.

What the research has examined

BPC-157 has the larger and more varied literature. In rats with transected Achilles tendons it was associated with higher load to failure, better functional scores and more complete repair than saline controls⁹. A 2019 review found consistently positive results across rodent tendon, ligament and muscle models, while noting that most studies came from a handful of research groups⁵. A large body of gastrointestinal work, mostly from the Zagreb group, covers ulcer, anastomosis and fistula models in rats¹.

For TB-500, most of what is quoted was learned from full-length thymosin beta-4, for example faster re-epithelialization, collagen deposition and angiogenesis in rat skin wounds¹⁰. Direct studies of the fragment are few. The synthetic peptide LKKTETQ promoted dermal repair in aged mice comparably to the parent protein¹¹, and the 2026 tendon study described below is the only musculoskeletal injury study of TB-500 we found in PubMed¹².

The head-to-head study

The only published experiment to compare the two directly is a 2026 rat study of Achilles tendon transection and repair¹². Thirty-two rats were randomized to four groups of eight (control, BPC-157, TB-500, and both peptides), with intraperitoneal administration for four weeks before biomechanical and histological testing. The authors described it as exploratory, with small groups and a single four-week time point¹². The main findings:

• Biomechanics: maximum load to failure was higher than control in both single-peptide groups, reaching statistical significance only for TB-500¹².
• Histology: TB-500 significantly lowered total Bonar and Movin scores, indicating less degenerative change; the combination significantly lowered Movin scores; BPC-157 lowered scores numerically without reaching significance¹².
• Collagen: type III collagen expression differed among groups, while type I collagen expression did not¹².
• Combination: giving both peptides did not outperform either one alone¹².

Human evidence

For BPC-157, a 2026 systematic review found three human studies with 30 participants in total: a retrospective knee-pain series, a retrospective interstitial cystitis series and a two-person intravenous safety pilot. All were uncontrolled, and the overall certainty of evidence was rated very low¹³.

For TB-500, we found no published human trial of the fragment. Clinical studies have used full-length thymosin beta-4, such as a small randomized, placebo-controlled phase 2 trial of thymosin beta-4 eye drops in nine patients with severe dry eye¹⁴. Those results cannot be transferred to a seven-residue fragment.

Which peptide fits which research question?

Because the two peptides were studied for different reasons, the literature points them at different questions. A study centered on actin dynamics, endothelial migration or angiogenesis assays has the clearest mechanistic rationale for the thymosin beta-4 fragment, provided it accounts for how the parent peptide is metabolized^7,8. A study of gastrointestinal lesions or of tendon and ligament repair in rats has far more BPC-157 precedent to build on^1,9.

A study that wants to test both has one published design to start from: the four-arm rat tendon experiment, which found no additive effect at four weeks¹². Its authors called for optimization and longer-term studies, so the absence of an additive effect at one time point is a starting hypothesis rather than a settled result. Whatever the design, reporting the identity and purity of each lot used makes results easier to compare, given the documented quality problems in this product category¹⁵.

Limitations of the evidence

Both literatures share weaknesses that matter more than any single result:

• Mostly rodents, small groups and short follow-up, for both peptides^5,12.
• Concentration of BPC-157 research in a few laboratories, with limited independent replication⁵.
• For TB-500, routine borrowing of findings from the full-length protein, and evidence that the fragment may act partly through its metabolites⁸.
• Product quality: TB500-labeled products bought online have been found not to consistently match their descriptions¹⁵, so identity testing belongs in any serious study design. Every Peptides Only lot ships with a lot-matched certificate of analysis (HPLC purity and mass-spec identity) from an independent lab, published in the COA library; our guide to reading a peptide COA explains what those results show.